The MarketWatch News Department was not involved in the creation of this content. Powered by the data and AI capabilities of SAS Viya, the life sciences solution streamlines drug development to ...

Powered by the data and AI capabilities of SAS Viya, the life sciences solution streamlines drug development to deliver new therapies to patients faster SAS Clinical Acceleration is now available to ...

Powered by the data and AI capabilities of SAS Viya, the life sciences solution streamlines drug development to deliver new therapies to patients faster SAS Clinical Acceleration empowers life ...

Leerink Partners analyst Mani Foroohar has maintained their bullish stance on RFM stock, giving a Buy rating yesterday. Mani Foroohar has given his Buy rating due to a combination of factors, ...

A randomized crossover trial of giving high-dose cisplatin with or without an overnight stay in hospital: Patients' preferences, quality of life, safety and resource use No significant financial ...